AGILENT TECHNOLOGIES, INC. Q1 FY2025 earnings call

Ignite Transformation Progress

• Created an Enterprise strategic-pricing organization for holistic pricing across solutions.
• Improved digital ecosystem with e-commerce upgrades, driving topline growth, and digital orders grew high-single-digits in Q1.
• Procurement teams identified significant cost-savings opportunities.

Organizational Health

• Removing management layers and increasing spans of control to become a nimbler organization for faster decision-making and innovation.

Customer Focus

• Collaborated with ABB Robotics for automated lab solutions to enhance customer productivity.
• Infinity III series saw strong adoption, with advanced automation and backward compatibility, creating replacement opportunities in the hundreds of millions of dollars.

Q1 Results

• Revenue of $1.681 billion increased 1% year-over-year, exceeding expectations. Instrument book-to-bill >1, a sign of market recovery. Exceeded expectations in all regions except Academia and Government. Food market grew 9% driven by China stimulus, PFAS grew 70% contributing 75 basis points of growth.

The Life Sciences and Diagnostics Markets Group grew 1% in the quarter, reporting $647 million. The Agilent CrossLab Group grew 3%, reporting $696 million, led by services. The Applied Markets Group reported $338 million in the quarter, a 2% decline but better than expected related to strong China stimulus orders.

Fiscal Year Guidance

• Maintained core growth guidance of 2.5%-3.5% for the year, incorporating prudence due to U.S. federal funding uncertainty.
• Adjusted full-year reported revenue to $6.68 billion to $6.76 billion due to U.S. dollar strengthening, adding $110 million in currency headwinds.

Second Quarter Guidance

• Guided revenue of $1.61 billion to $1.65 billion, with core growth 2.5%-5% and reported growth 2.4%-4.9%. Non-GAAP EPS expected to be between $1.25 and $1.28.

• Uncertainty over U.S. federal funding environment, though it's a small part of the business. - Impact of tariffs, with actions taken to mitigate, but still monitoring the effect.

Q: Rachel Vatnsdal asked about prudence in guidance and impact of funding risk.

A: Padraig McDonnell and Bob McMahon discussed prudent guidance, minimal impact from funding so far, and sales team activity.

Q: Unidentified Analyst asked about PFAS growth and Europe packaging regulation.

A: Padraig McDonnell and Bob McMahon talked about strong PFAS demand, growth in various markets, and Europe's strength.

Q: Patrick Donnelly asked about China stimulus traction and NASD business.

A: Padraig McDonnell and Simon May discussed China stimulus win rates and NASD demand being in-line with expectations.

Q: Jack on for Tycho Peterson asked about replacement cycle and Infinity III.

A: Padraig McDonnell and Robert W. McMahon talked about replacement cycle momentum and early positive impacts of Infinity III.

Q: Jack Meehan asked about management layer changes and BIOVECTRA integration.

A: Padraig McDonnell and Simon May discussed management layer changes for faster decision-making and BIOVECTRA integration progress.

Q: Vijay Kumar asked about book-to-bill trends.

A: Robert W. McMahon explained book-to-bill above one as a sign of market recovery.

Q: Puneet Souda asked about China stimulus and margin contribution from Ignite.

A: Padraig McDonnell and Robert W. McMahon discussed China stimulus expectations and Ignite margin expansion targets.

Q: Doug Schenkel asked about December/January trends and tariff actions.

A: Padraig McDonnell and Simon May talked about December momentum and tariff mitigation actions.

Q: Dan Leonard asked about pharma CapEx and tariff actions.

A: Padraig McDonnell and Simon May discussed pharma CapEx areas and tariff mitigation details.

Q: Eve Burstein asked about academic government softness and GC upcycle.

A: Padraig McDonnell and Mike Zhang talked about academic government softness trends and GC market opportunities.